The Effect of Colchicine on Inflammation in ACS Patients

Inclusion Criteria: * male or female * \>18 yrs * STEMI patients who were successfully treated with PCI. Exclusion Criteria: * Pregnant or breast-feeding women or women of childbearing potential. * Active inflammatory, known malignancy, infectious diseases or current treatment with corticosteroids or anti inflammatory agents. * Known hypersensitivity to colchicine or current chronic treatment with colchicine. * Severe renal failure (estimated creatinine clearance \<30ml/min) or hepatic failure (Child Pugh score B or C ) * Cardiac arrest, ventricular fibrillation, cardiogenic shock or previous myocardial infarction. * Patients using the following agents: Strong CYP3A4 inhibitors (ritonavir, clarithromycin, ketoconazole, voriconazole, itraconazole), intermediate CYP3A4 inhibitors (aprepitant, diltiazem, erythromycin, fluconazole, verapamil), P-gp inhibitor (amiodarone, clarithromycin, erythromycin, azithromycin, ranolazine, verapamil, ketoconazole, itraconazole) and grape fruit juice